📅 PUBMED DAILY TRIAGE — 2026-04-17

Window: 2026-04-16T09:00:00Z → 2026-04-17T09:00:00Z (CRDT) Topics scanned: 9 | Articles reviewed: ~55 candidates | Classified: 15 High priority: 3 | Standard: 7 (+ 4 LOW-standard 4/10) | Low/archive: 1 | Unsolicited finds: 0 Run status: PARTIAL_SUCCESS (aging/longevity, rare disease, and sentinel scan IDs identified but abstracts not retrieved)

🔴 HIGH PRIORITY (flag-elevated) — Early Cancer Detection

No articles scored ≥8 today. All 3 HIGH articles are flag-elevated via EARLY_CANCER_DETECTION.

Early Cancer Detection (Liquid Biopsy / ctDNA / cfDNA)

TR-2026-04-17-001 · PMID 41988016 · Score 7/10 · 🔴 EARLY_CANCER_DETECTION

EV-DNA and ctDNA compared in cancer detection meta-analysis — 12 studies, 765 patients. EV-DNA shows sensitivity 64.6% / specificity 93.3% vs ctDNA 70% / 90.6%. EV-DNA is a viable complementary liquid biopsy biomarker, not replacement. J Extracell Biol (PMC open access). Systematic review + meta-analysis.

TR-2026-04-17-002 · PMID 41991387 · Score 5/10 · 🔴 EARLY_CANCER_DETECTION

Platelet-based liquid biopsy for ovarian cancer — MD Anderson review in Trends Cancer proposing circulating platelet molecular/functional signatures as next-generation ovarian cancer biomarkers. Addresses critical unmet need (ovarian cancer diagnosed late in ~75% of cases). Conceptual/emerging evidence stage.

TR-2026-04-17-003 · PMID 41990988 · Score 5/10 · 🔴 EARLY_CANCER_DETECTION

cfDNA/ctDNA in HCC liver transplantation — Cleveland Clinic review synthesizing evidence for ctDNA detecting HCC recurrence 3-8 months pre-radiographic progression. Identifies 7 concrete implementation barriers (platform heterogeneity, 7-14d turnaround, no reimbursement pathway). Actionable roadmap for clinical integration. J Gastrointest Surg.

🟢⚪ STANDARD (5-7) — Top by Topic

AI/ML in Clinical Diagnostics

TR-2026-04-17-004 · PMID 41992007 · 7/10 · Genomics/Precision Medicine

GBM spatial TME atlas — n=100 patients, 121 spatial transcriptomics profiles, Nature Neuroscience. Identifies 4 malignant cellular communities; MES-Hyp/MES-Ast subpopulations with distinct vascular niches; neuron–OPC synaptic connections validated. Largest multi-modal GBM atlas to date.

TR-2026-04-17-005 · PMID 41991402 · 7/10 · Diagnostics

AI vs GP in diabetic retinopathy screening — n=500 T2DM, cross-sectional. EyeArt v3.0.0 AI: 98.2% sensitivity, 98.9% specificity, κ=0.91 vs ophthalmologist; outperforms GPs (κ=0.84, sensitivity 86.4%). 100% sensitivity for moderate-to-severe DR. 🟢 NEAR_TERM_IMPLEMENTABLE pending multicentre validation.

Hematologic Malignancies / AI

TR-2026-04-17-006 · PMID 41991742 · 6/10 · Treatment Innovation

IRF4-PAICS-LDHA axis in DLBCL — ML-driven single-cell transcriptomics identifies metabolic-immune axis; methotrexate and LDHA knockdown reverse T cell exhaustion + suppress tumor growth. Multi-targetable hub. NPJ Precision Oncol.

Novel Therapeutics / Immunotherapy

TR-2026-04-17-007 · PMID 41992060 · 6/10 · Treatment Innovation

NK cell subsets + JAB1 in NPC — CD16+CD57+ NK cells prognostic; JAB1 enhances NK cytotoxicity; JAB1/CD107a superior to SCC/CEA as biomarkers. British Journal of Cancer.

Hematologic Malignancies (crosscutting)

TR-2026-04-17-008 · PMID 41991899 · 5/10 · Prevention

Pediatric OTC fertility preservation in oncology — 15y retrospective, n=159 girls/adolescents, 22% leukemia/lymphoblastic lymphoma. POI 43% of evaluable patients. Structured risk-stratified program model. 🟡 UNDERSERVED_POPULATION.

Cardiovascular-Metabolic

TR-2026-04-17-009 · PMID 41990305 · 5/10 · Public Health

Seasonal AF outcomes — n=13,629 prospective, Spain (2 climate zones, 2y follow-up). Summer protective vs winter; extreme heat raises ischemic stroke risk 3.6×. Clinical guidance for anticoagulated AF patients. 🟢 NEAR_TERM_IMPLEMENTABLE.

TR-2026-04-17-010 · PMID 41992025 · 5/10 · Drug Development

Tirzepatide paradox in hypertensive rats — Tirzepatide elevates BP by +44 mmHg and induces LV hypertrophy/fibrosis via POMC sympathetic activation in non-obese hypertensive model. Contrasts clinical CV benefit in obese. Safety signal for non-standard indications. Hypertens Res.

💡 UNSOLICITED FINDS

None identified in this run (sentinel scan IDs retrieved but abstracts not reviewed — deferred to next run).

📊 TODAY'S BREAKDOWN

By research category:

• Early Detection: 3 | Treatment Innovation: 4 | Diagnostics: 3 | Public Health: 2 | Drug Development: 2 | Genomics/Precision Medicine: 1 (crossover)

By evidence maturity:

• Validated: 5 | Exploratory: 9 | (Potentially Practice-Changing: 0)

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed: 15 | preprint: 0

Topics with zero 8+ articles this run: All topics. Best score: 7/10 (liquid biopsy meta-analysis, GBM spatial transcriptomics, AI DR screening).

🔧 RUN NOTES

• Window expansion NOT triggered (≥5 relevant records found).
• Partial failure — 3 topics incomplete:
  • Aging/longevity/population health: 187 IDs found; abstract retrieval deferred due to API capacity. Top deferred IDs: 41991262, 41991222, 41990957, 41992059, 41992042.
  • Rare diseases: 5 IDs found (41990887, 41990758, 41990239, 41988806, 41986945); deferred.
  • Sentinel scan: 104 IDs found; deferred.
• CBC/ML hematology: 11th consecutive run with ZERO results. Persistent sparse topic. Recommend 7-day window expansion for this topic specifically in next run.
• 1 record discarded (PMID 41991818 — cognitive psychology paper matching hematology search via AML journal abbreviation quirk).
• PMID 41987223 (liquid biopsy topic, 4th result) not retrieved; deferred to next run.
• All 3 HIGH articles are flag-elevated (EARLY_CANCER_DETECTION), not score-elevated. No triage score reached 8+ today.
• Rolling 7-day view: CBC/ML hematology producing 0 high-priority articles for 11+ consecutive runs; consider watchlist query refinement.